TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2287792

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 16 mg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 4 mg intranasally for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1 mg or 16 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (general)
Number of subjects: 0
Study: 6756709

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 17
Study: 30877128

Group type: EXPERIMENTAL
Intervention: Patient-centred intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30060900

Group type: EXPERIMENTAL
Intervention: Liquid dissection technique
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional dissection technique
Number of subjects: 29
Study: 27261986

Group type: EXPERIMENTAL
Intervention: Focused meditation (8-week program with weekly 75 min classes)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Self-care exercise program (with wait-list offer for meditation)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Focused meditation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Self-care exercise program
Number of subjects: 68
Study: 25159926

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FMSRP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Partial-mouth scaling and root planing (PMSRP)
Number of subjects: 34
Study: 22826983

Group type: EXPERIMENTAL
Intervention: FAM (fluorouracil, doxorubicin, mitomycin C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CDDP, FU/FA (cisplatin, 5‐fluorouracil, leucovorin)
Number of subjects: 50
Study: 20586923

Group type: EXPERIMENTAL
Intervention: Abciximab bolus followed by a 12-h placebo infusion and concomitant 600-mg clopidogrel
Number of subjects: 73

Group type: COMPARATOR
Intervention: Abciximab bolus + a 12-h infusion and 300 mg of clopidogrel
Number of subjects: 73
Study: 17368341

Group type: EXPERIMENTAL
Intervention: Lateral compaction technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single-cone technique
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Canal type (mandibular distal canal)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Canal type (mandibular mesial canal)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Canal type (maxillary palatal canals)
Number of subjects: 36
Study: 15726575

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTXA) injection with low-frequency electrical nerve stimulation (NS) at 4 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTXA) injection with high-frequency electrical nerve stimulation (NS) at 25 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Botulinum toxin type A (BTXA) injection without electrical nerve stimulation (NS)
Number of subjects: 0
Study: 11927114

Group type: EXPERIMENTAL
Intervention: Full dose of Yuzpe regimen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Half dose of Yuzpe regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Yuzpe regimen (both doses)
Number of subjects: 60
Study: 9862249

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenous bolus)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients with impaired adrenal function reserve
Number of subjects: 15

Group type: COMPARATOR
Intervention: Septic patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 15
Study: 7614641

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 20
Study: 2651178

Group type: EXPERIMENTAL
Intervention: Controlled release salbutamol tablets (8 mg twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sustained release theophylline preparation (400-800 mg given once each night)
Number of subjects: 32
Study: 154872

Group type: COMPARATOR
Intervention: oral antibiotic + topical placebo lotion
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: oral antibiotic + topical ethyl lactate lotion
Number of subjects: 45

Group type: COMPARATOR
Intervention: topical ethyl lactate lotion only
Number of subjects: 45
Study: 31298169

Group type: EXPERIMENTAL
Intervention: START intervention (an eight-session manual-based coping intervention delivered by supervised psychology graduates)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 260
Study: 30722036

Group type: EXPERIMENTAL
Intervention: GroupCoreDIST intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 28598910

Group type: EXPERIMENTAL
Intervention: Power training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 12
Study: 25441065

Group type: EXPERIMENTAL
Intervention: MIS-RDAVR (Minimally Invasive Rapid Deployment Aortic Valve Replacement)
Number of subjects: 94

Group type: COMPARATOR
Intervention: FS-AVR (Conventional Full Sternotomy Aortic Valve Replacement)
Number of subjects: 94
Study: 23147203

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Spiritual interventions
Number of subjects: 847

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 847
Study: 20923909

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) with a 25% reduction of ad libitum energy intake over 2 years
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 225
Study: 19433757

Group type: EXPERIMENTAL
Intervention: High-calorie-expenditure exercise (3000-3500 kcal/wk)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard CR exercise (700-800 kcal/wk)
Number of subjects: 74
Study: 16684121

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 8
Study: 14651947

Group type: EXPERIMENTAL
Intervention: Stress (Stroop test)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Relaxation (tape)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (video)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Capsaicin injection
Number of subjects: 50
Study: 11703863

Group type: EXPERIMENTAL
Intervention: Whole Blood (WB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Buffy Coat-Poor Packed Red Cells and Fresh-Frozen Plasma (RCP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-Transfused (NT)
Number of subjects: 60
Study: 9237055

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 193
Study: 7488359

Group type: EXPERIMENTAL
Intervention: Colgate Winterfresh Gel with 0.76% sodium monofluorophosphate (MFP)
Number of subjects: 2222

Group type: EXPERIMENTAL
Intervention: Crest Regular Flavor Toothpaste with 0.24% sodium fluoride (NaF)
Number of subjects: 2222

Group type: EXPERIMENTAL
Intervention: Colgate Junior Toothpaste with 0.243% sodium fluoride (NaF)
Number of subjects: 2222
Study: 3328680

Group type: EXPERIMENTAL
Intervention: Nimodipine 1.0 microgram kg‐1 min‐1 (Group 1, n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nifedipine 0.70 microgram kg‐1 min‐1 (Group 2, n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No calcium channel blocker (Group 3, n = 15)
Number of subjects: 45
Study: 29525970

Group type: EXPERIMENTAL
Intervention: Stopping oral bisphosphonate treatment (ibandronate, alendronate, risedronate)
Number of subjects: 0
Study: 26073181

Group type: EXPERIMENTAL
Intervention: Mirogabalin (DS-5565)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregabalin (150 mg, dosed twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirogabalin (17.7 mg estimated dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirogabalin (twice-daily dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirogabalin
Number of subjects: 0
Study: 25555537

Group type: EXPERIMENTAL
Intervention: Positive mood vodcast
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition (blue static background, neutral music, and script describing objective facts)
Number of subjects: 42
Study: 23607837

Group type: EXPERIMENTAL
Intervention: Immunophenotyping and protein profiling of airway casts
Number of subjects: 0
Study: 20622383

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day of Fungisome
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day of Fungisome
Number of subjects: 10
Study: 18705811

Group type: EXPERIMENTAL
Intervention: BCP (biphasic calcium phosphate)
Number of subjects: 37

Group type: COMPARATOR
Intervention: ABB (anorganic bovine bone)
Number of subjects: 37
Study: 17078006

Group type: EXPERIMENTAL
Intervention: Combination probiotics and nutrients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 15579984

Group type: EXPERIMENTAL
Intervention: Transpupillary frequency‐doubled Nd:YAG laser retinopexy
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Cryotherapy for retinopexy
Number of subjects: 703
Study: 11369844

Group type: EXPERIMENTAL
Intervention: Early intervention with epoetin beta (Hb level 11‐12.5 g/dl, target Hb 13‐15 g/dl)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Late intervention with epoetin beta (Hb level <10.5 g/dl, target Hb 10.5‐11.5 g/dl)
Number of subjects: 600
Study: 9416886

Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine (3 g/d) for 7 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine combined with simvastatin for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Home diet (control)
Number of subjects: 32
Study: 8512911

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) applied to one side of the mouth after surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (non-operating model) applied to the other side of the mouth after surgery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (non-operating model)
Number of subjects: 64
Study: 2979215

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine at 10 ng ml-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine at 30 ng ml-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine at 90 ng ml-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentagastrin 0.1 micrograms kg-1.hour with famotidine at 4.3 micrograms kg-1.hour
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pentagastrin 2.0 micrograms kg-1.hour with famotidine at 4.3 micrograms kg-1.hour
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31355957

Group type: EXPERIMENTAL
Intervention: Tailored self-management resources
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 29565636

Group type: EXPERIMENTAL
Intervention: Usual Care + Homeopathy Treatment (UC + HT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 60
Study: 26693800

Group type: EXPERIMENTAL
Intervention: DHAP (dexamethasone, high-dose cytarabine, cisplatin)
Number of subjects: 266
Study: 24527578

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine treatment
Number of subjects: 225

Group type: COMPARATOR
Intervention: Regular Western and Chinese medicine treatments
Number of subjects: 225
Study: 22182482

Group type: EXPERIMENTAL
Intervention: Diet low-ratio (LR) - n-6:n-3 = 1.7:1
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diet high-ratio (HR) - n-6:n-3 = 30:1
Number of subjects: 11
Study: 19933991

Group type: EXPERIMENTAL
Intervention: Diabetes Care Protocol (DCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18929505

Group type: COMPARATOR
Intervention: 3 months of maximum short-term androgen deprivation (STAD) before and during radiation
Number of subjects: 802

Group type: COMPARATOR
Intervention: 6 months of maximum short-term androgen deprivation (STAD) before and during radiation
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Time to biochemical failure (TTBF)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen doubling time (PSADT)
Number of subjects: 802
Study: 15765242

Group type: EXPERIMENTAL
Intervention: Gymnasts
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study: 11982446

Group type: EXPERIMENTAL
Intervention: Citalopram medication
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both treated groups (Citalopram and Cognitive-behavioral therapy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Responders (regardless of treatment approach)
Number of subjects: 18
Study: 9789193

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8552510

Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (0.015 g/kg body weight)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 42
Study: 2199589

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 995333

Group type: EXPERIMENTAL
Intervention: Preinduction scoring systems (five systems evaluated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preinduction score modifiers
Number of subjects: 0
Study: 31394106

Group type: EXPERIMENTAL
Intervention: Personalized advice (PA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Generic advice (GA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both PA and GA
Number of subjects: 59
Study: 27913260

Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG) test
Number of subjects: 109

Group type: COMPARATOR
Intervention: Patient-Reported Outcome Measures (PROMs)
Number of subjects: 109
Study: 26123142

Group type: EXPERIMENTAL
Intervention: Droperidol 2.5mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Metoclopramide 10mg (Control)
Number of subjects: 180
Study: 26591709

Group type: EXPERIMENTAL
Intervention: Fistulectomy (Group A)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Fistulotomy with marsupialisation (Group B)
Number of subjects: 162
Study: 21779973

Group type: EXPERIMENTAL
Intervention: Psyllium (3.6 g × 2/day) during rehabilitation
Number of subjects: 45

Group type: COMPARATOR
Intervention: High-fiber diet (approximately 30 g fiber per day) during rehabilitation
Number of subjects: 45
Study: 20051465

Group type: EXPERIMENTAL
Intervention: Mandometer (computerised device providing real time feedback during meals)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mandometer
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 106
Study: 17848908

Group type: EXPERIMENTAL
Intervention: Audiovisual patient information (AVPI)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standard written information
Number of subjects: 173
Study: 15313811

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (untreated lesions)
Number of subjects: 31
Study: 11571862

Group type: EXPERIMENTAL
Intervention: Sulfamethizole
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Trimethoprim + Sulfamethizole
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mecillinam
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 69
Study: 9758264

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg)‐containing multivitamin supplementation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg)‐containing multivitamin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physiological dose (<1 mg) of folic acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Another multivitamin (not specified)
Number of subjects: 60
Study: 7921862

Group type: EXPERIMENTAL
Intervention: Sufentanil (10 micrograms)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no opioids)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 156
Study: 2970360

Group type: EXPERIMENTAL
Intervention: Human atrial natriuretic peptide (alpha-hANP; 100 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study: 4359162

Group type: EXPERIMENTAL
Intervention: l(‐) amphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d(+) amphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: clomipramine with either amphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: l(‐) amphetamine and d(+) amphetamine
Number of subjects: 12
Study: 31943197

Group type: EXPERIMENTAL
Intervention: Amitriptyline (10 to 50 mg daily)
Number of subjects: 50
Study: 31340634

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT), Group 1, n = 37
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham taping, Group 2, n = 37
Number of subjects: 74
Study: 28148255

Group type: EXPERIMENTAL
Intervention: TASSH training
Number of subjects: 64
Study: 25687111

Group type: EXPERIMENTAL
Intervention: Problem-focused coping strategies
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Higher socioeconomic status
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Female gender of the adolescent
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Fewer children in the home
Number of subjects: 125

Group type: COMPARATOR
Intervention: Adolescent TBI severity
Number of subjects: 125

Group type: COMPARATOR
Intervention: Caregiver depression
Number of subjects: 125
Study: 24040767

Group type: EXPERIMENTAL
Intervention: Retransfusion of unwashed cardiotomy suction blood (mean volume 280 ml, corresponding to 5% of blood volume)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ex vivo addition of 10% and 20% suction blood to systemic blood
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cardiotomy suction blood
Number of subjects: 30

Group type: COMPARATOR
Intervention: Systemic blood
Number of subjects: 30
Study: 21406278

Group type: EXPERIMENTAL
Intervention: Community-university partnership model
Number of subjects: 11960

Group type: COMPARATOR
Intervention: Usual-programming conditions
Number of subjects: 11960
Study: 19522261

Group type: EXPERIMENTAL
Intervention: Perioperative epidural buprenorphine 0.2 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: General anesthesia only (control group)
Number of subjects: 28
Study: 17087192

Group type: EXPERIMENTAL
Intervention: Laser-based 13C-urea breath test (13C-UBT)
Number of subjects: 0
Study: 15530758

Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11765143

Group type: EXPERIMENTAL
Intervention: Capsule formulation (500 mg sitafloxacin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous formulation (400 mg sitafloxacin)
Number of subjects: 0
Study: 9267668

Group type: EXPERIMENTAL
Intervention: Paclitaxel 170 mg/m2 and Cyclophosphamide 2 gm/m2
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 and Cyclophosphamide 3 gm/m2
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Prior chemotherapy regimen (1 vs more than 1)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Prior radiation therapy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patient performance status
Number of subjects: 141
Study: 8488991

Group type: EXPERIMENTAL
Intervention: etomidate in lipid emulsion formulation (Lipofundin MCT 20%; eto-lip)
Number of subjects: 100

Group type: COMPARATOR
Intervention: etomidate in propylene glycol 35% (eto-pg)
Number of subjects: 100
Study: 3449066

Group type: EXPERIMENTAL
Intervention: Ambroxol, 3 x 30 mg for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gelomyrtol forte, 4 x 1 capsule (1 capsule = 0.3 g Myrtol, standardized to at least 20 mg of alpha-pinene, 75 mg of limonene, and 75 mg of cineole) for 7 days
Number of subjects: 0
Study: 29475197

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choi criteria for tumour response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incidence of distant metastasis (DM)
Number of subjects: 0
Study: 27619632

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 256

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 256
Study: 24976097

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy ± intrasinus thrombolysis (MT ± IST)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intrasinus thrombolysis (IST) alone
Number of subjects: 63
Study: 23134522

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg plus valsartan 80 mg (N + V)
Number of subjects: 359

Group type: COMPARATOR
Intervention: High-dose valsartan (160 mg) monotherapy (V160)
Number of subjects: 359
Study: 20831738

Group type: EXPERIMENTAL
Intervention: Dentists received background information about the patient prior to the dental visit (n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Dentists did not receive background information about the patient prior to the dental visit (n = 28)
Number of subjects: 57
Study: 19026302

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg plus ezetimibe 10 mg
Number of subjects: 196

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 196
Study: 15808114

Group type: EXPERIMENTAL
Intervention: SIT with modified Dermatophagoides pteronyssinus 100 % allergen vaccine (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (pharmacological treatment only, n = 25)
Number of subjects: 50